PMA supplement
P200011 S002: ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA)
FDA PMA supplement · Real-Time Process · Pillar Biosciences
Key facts
| Original PMA | P200011 |
|---|---|
| Supplement number | S002 |
| Supplement type | Real-Time Process |
| Reason for the supplement | Labeling Change - Indications/instructions/shelf life/tradename |
| Trade name | ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) |
| Generic name | Next generation sequencing oncology panel, somatic or germline variant detection system |
| Applicant | Pillar Biosciences |
| Product code | PQP |
| Received date | Jul 23, 2024 |
| Decision date | Sep 27, 2024 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: